Skip to main content

Drug Interactions between ixazomib and Kimyrsa

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

oritavancin ixazomib

Applies to: Kimyrsa (oritavancin) and ixazomib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ixazomib, which is a substrate of the isoenzyme. When ixazomib was administered with the potent CYP450 3A4 inducer rifampin, ixazomib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 54% and 74%, respectively.

MANAGEMENT: The potential for diminished pharmacologic effects of ixazomib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

Drug and food interactions

Moderate

ixazomib food

Applies to: ixazomib

Food may interfere with the absorption of ixazomib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take ixazomib at least 1 hour before or 2 hours after eating. On days when you take both ixazomib and dexamethasone, make sure you do not take them at the same time, since ixazomib should be taken on an empty stomach while dexamethasone should be taken with food to prevent irritation and injury to the stomach.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer